TAAR1 and Sepsis: Five higher-quality studies (1568 patients with sepsis) showed no significant benefit of Tα1 therapy (OR 0.82, 95% CI: 0.65–1.03, P = 0.09), while six lower-quality studies (359 patients) demonstrated a significant reduction in 28-day mortality (OR 0.41, 95% CI: 0.24–0.68, P = 0.0007, Figure 2B).